Recent insider trends for VistaGen Therapeutics, Inc. (NASDAQ:VTGN) have caught the attention of investors. Analysts monitor insider data to understand the sentiment of a company’s largest and most important shareholders. VTGN’s insider trading patterns have some implications for where the stock might be headed.
Institutions own 14.90% of VistaGen Therapeutics, Inc. (VTGN)’s shares. The total value of these holdings, in millions, is $2. Among active positions in the latest quarter, 4 holders increased their positions by a total of 541399 shares, 3 holders decreased the positions by a total of 32012 shares, and 9 holders held their positions. This works out to a net increase in ownership of 509387 shares, and suggests that institutions are feeling bullish about the stock.
Among new and sold out positions, 2 holders initiated new positions by a total of 23390 shares and 2 holders exited their positions by a total of 26116 shares. This nets out to a decrease of 2726 shares and is another bearish sign for VTGN.
Insider ownership increased by a total of 0 shares, which suggests that VTGN’s key executives are feeling more optimistic about the outlook for the stock. The data from the past twelve months tells a similar story: insiders executed 1 buys, and ownership increased by a net of 100000 shares.
Short interest, or the number of a stock’s tradable shares currently being shorted, is another metric investors use to get a pulse on sentiment. VistaGen Therapeutics, Inc. (NASDAQ:VTGN)’s short interest is 498000 shares, or 9.57% of the float. This represents an increase of 42% in the number of shares being shorted compared to the previous reading, and implies that investors felt more pessimistic about the stock during the past two weeks.
In light of the insider ownership and trading data it makes sense to consider technicals to see if they come to a similar conclusion about the outlook for VTGN. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that VTGN is a buy, which implies that VTGN is expected to outperform the market based on prior trading patterns.
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators (also) suggest that VistaGen Therapeutics, Inc. (NASDAQ:VTGN) is undervalued.